Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.625 USD | -1.76% | +9.42% | -14.49% |
03:40pm | CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate | MT |
May. 23 | CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.49% | 827M | |
+52.93% | 63.85B | |
-2.53% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.22% | 26.52B | |
-21.41% | 18.69B | |
+2.62% | 12.73B | |
+22.42% | 12.11B | |
+27.60% | 12.07B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study